Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
D 66.94 -0.06% -0.04
GILD closed down 0.06 percent on Friday, January 22, 2021, on 54 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 2
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical GILD trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Weak + Overbought Other -0.06%
Overbought Stochastic Strength -0.06%
Jack-in-the-Box Bullish Bullish Swing Setup -1.54%
Upper Bollinger Band Walk Strength -1.54%
Weak + Overbought Other -1.54%
Inside Day Range Contraction -1.54%
Above Upper BB Strength -1.54%
Older End-of-Day Signals for GILD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Gilead Sciences, Inc. Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Diseases Inflammation Hypertension Antibiotic Influenza Infection Macular Degeneration Coronavirus Cardiovascular Disease Cystic Fibrosis Organic Chemistry Vascular Diseases HIV Cardiovascular Diseases Pulmonary Arterial Hypertension Liver Disease Respiratory Disease Immunodeficiency Oligonucleotide Perfusion Hepatotoxins Respiratory Diseases Retinitis Angina Gilead Sciences Fungal Infection Prodrugs Fungal Infections Cytomegalovirus Retinitis Myocardial Perfusion Imaging Oncology Diseases Tenofovir Disoproxil Treatment Of Cardiovascular Disease Treatment Of Life Threatening Diseases

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 85.97
52 Week Low 56.56
Average Volume 9,046,706
200-Day Moving Average 68.18
50-Day Moving Average 60.75
20-Day Moving Average 61.57
10-Day Moving Average 64.39
Average True Range 1.48
ADX 40.74
+DI 39.00
-DI 9.75
Chandelier Exit (Long, 3 ATRs ) 63.70
Chandelier Exit (Short, 3 ATRs ) 61.01
Upper Bollinger Band 68.79
Lower Bollinger Band 54.36
Percent B (%b) 0.87
BandWidth 23.43
MACD Line 1.89
MACD Signal Line 1.14
MACD Histogram 0.7488
Fundamentals Value
Market Cap 83.91 Billion
Num Shares 1.25 Billion
EPS 1.01
Price-to-Earnings (P/E) Ratio 66.47
Price-to-Sales 3.24
Price-to-Book 4.28
PEG Ratio 0.43
Dividend 2.72
Dividend Yield 4.06%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.79
Resistance 3 (R3) 68.76 68.11 68.48
Resistance 2 (R2) 68.11 67.64 68.13 68.37
Resistance 1 (R1) 67.53 67.35 67.82 67.56 68.27
Pivot Point 66.88 66.88 67.03 66.90 66.88
Support 1 (S1) 66.30 66.41 66.59 66.33 65.61
Support 2 (S2) 65.65 66.12 65.67 65.51
Support 3 (S3) 65.07 65.65 65.40
Support 4 (S4) 65.10